Fenofibrate: PPARα Agonist for Dyslipidemia
Fenofibrate is a prodrug of fenofibric acid, a peroxisome proliferator-activated receptor alpha (PPARα) agonist. Activation of PPARα modulates the transcription of genes involved in lipid metabolism, resulting in reduced triglyceride synthesis, enhanced lipoprotein lipase activity, and increased HDL cholesterol production. Fenofibrate is the most widely prescribed fibrate globally.
Product Profile
| CAS Number | 49562-28-9 |
|---|---|
| Molecular Formula | C20H21ClO4 |
| Appearance | White crystalline powder |
| Therapeutic Category | Lipid-lowering agent (fibrate) |
| Storage | Room temperature, protect from moisture |
Applications
Fenofibrate is indicated for the treatment of hypertriglyceridemia (Fredrickson types IV and V) and mixed dyslipidemia. It is used as an adjunct to diet when statins alone are insufficient to control triglycerides or raise HDL. Fenofibrate also reduces elevated uric acid levels, an independent cardiovascular risk factor. Various formulations exist with different bioavailability profiles: micronized capsules (200 mg), nanocrystal tablets (145 mg), and choline salt formulations (135 mg fenofibric acid). All aim to reduce the high-fat meal dependency of absorption. Combination therapy with statins (particularly rosuvastatin) is used for refractory mixed dyslipidemia.
Why Source from TCS
TCS supplies fenofibrate to pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Fenofibrate 49562-28-9?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Fenofibrate 49562-28-9 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Fenofibrate 49562-28-9?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.